Brief: Paratek Pharmaceuticals Announces Initiation Of Funding From Barda For All FDA Required Post-Marketing Studies For Nuzyra
02/04/2020 14:10
April 2 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES INITIATION OF FUNDING
FROM
BARDA FOR ALL FDA REQUIRED POST-MARKETING STUDIES FOR NUZYRA•
(OMADACYCLINE)
* PARATEK PHARMACEUTICALS INC - REIMBURSEMENT COST FOR
POST-MARKETING COMMITMENTS IS PROJECTED TO TOTAL APPROXIMATELY
$77 MILLION
Source text for Eikon: ID:nGNX45k5TW
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million